Montelukast suppresses NLRP3 inflammasome activation as a potential prophylactic agent against gout arthritis flares
Authors:
Open Access
- 12 February 2026
- journal article
- research article
- Published by Springer Nature in Journal of Inflammation
- Vol. 23 (1)
Abstract
Gout arthritis (GA) flares are unexpected bouts of heat, swelling, and redness resulting in excruciating pain caused by monosodium urate (MSU) crystal depoKeywords
This publication has 38 references indexed in Scilit:
- Montelukast attenuated memory decline, neuroinflammatory and neurodegenerative biomarkers in Aβ1−42 exposed model of alzheimer’s disease in micePsychopharmacology, 2025
- New insights on pharmacological potential of montelukast: a comprehensive reviewInflammopharmacology, 2025
- Montelukast Use and the Risk of Neuropsychiatric Adverse Events in ChildrenJAMA Pediatrics, 2025
- Protective effect of leukotriene receptor antagonist, montelukast, against cyclophosphamide-induced placental toxicity via modulation of NLRP3/IL-1β signaling pathway in ratsInternational Immunopharmacology, 2024
- Ameliorative effect of montelukast against STZ induced diabetic nephropathy: targeting HMGB1, TLR4, NF-κB, NLRP3 inflammasome, and autophagy pathwaysInflammopharmacology, 2023
- Analysis of Neuropsychiatric Diagnoses After Montelukast InitiationJAMA Network Open, 2022
- Risk of Psychiatric Adverse Events Among Montelukast UsersThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- Estimation of Primary Prevention of Gout in Men Through Modification of Obesity and Other Key Lifestyle FactorsJAMA Network Open, 2020
- Montelukast inhibits oxidized low-density lipoproteins (ox-LDL) induced vascular endothelial attachment: An implication for the treatment of atherosclerosisBiochemical and Biophysical Research Communications, 2017
- Suppressive effect of Withania somnifera root powder on experimental gouty arthritis: An in vivo and in vitro studyChemico-Biological Interactions, 2006